Skip to main content

What the FDA labels say about taking them together

Heparin and palifermin

Palifermin's FDA label of December 17, 2025 names heparin in its drug interactions section; the heparin labels PlainMeds reads (4) do not name palifermin. The palifermin label: “Heparin increases systemic exposure; flush intravenous line between heparin and Kepivance. Do not administer within 24 hours of myelotoxic chemotherapy.”

Check it at the source: the heparin FDA label on DailyMed (effective November 28, 2025, Fresenius Kabi USA, LLC); the palifermin FDA label on DailyMed (effective December 17, 2025, Swedish Orphan Biovitrum AB (publ)).

What does the heparin label say about palifermin?

Heparin's label (effective November 28, 2025) and its 3 other brand-application labels do not name palifermin in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Heparin Sodium), Fresenius Kabi USA, LLC, effective November 28, 2025 (SPL set d55b4a63-0c04-4874-b74f-9e9b9e8b008c), via openFDA; the full label on DailyMed

What does the palifermin label say about heparin?

Palifermin label, drug interactions

Heparin increases systemic exposure; flush intravenous line between heparin and Kepivance. ( 7 ) Do not administer within 24 hours of myelotoxic chemotherapy.

Source: FDA drug label (KEPIVANCE), Swedish Orphan Biovitrum AB (publ), effective December 17, 2025 (SPL set 426f6e64-2c20-4a61-6d65-7320426f6e64), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

18Heparin generic labelers
0Palifermin generic labelers
HeparinPalifermin
Labeled forBlood clots (DVT and PE), Atrial fibrillationn/a
Boxed warningNoNo
Pharmacy cost (NADAC)$1.18 per mL 5,000 unit/mL vialn/a
Shortage nowIn shortageNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?